Filing Details

Accession Number:
0000899866-17-000161
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-05 20:28:16
Reporting Period:
2017-08-31
Accepted Time:
2017-09-05 19:28:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
899866 Alexion Pharmaceuticals Inc ALXN Pharmaceutical Preparations (2834) 133648318
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1630299 Julie O'neill C/O Alexion Pharmaceuticals, Inc
100 College Street
New Haven CT 06510
Evp. Global Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $.0001 Per Share Disposition 2017-08-31 612 $142.00 26,092 No 4 S Direct
Common Stock, Par Value $.0001 Per Share Disposition 2017-09-05 1,841 $145.81 24,251 No 4 S Direct
Common Stock, Par Value $.0001 Per Share Disposition 2017-09-05 672 $147.00 23,579 No 4 S Direct
Common Stock, Par Value $.0001 Per Share Disposition 2017-09-05 600 $145.64 22,979 No 4 S Direct
Common Stock, Par Value $.0001 Per Share Disposition 2017-09-05 650 $145.81 22,329 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
  2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $142.00 - $142.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
  3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $145.51 - $146.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
  4. This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.